ライフサイエンスコーパス: birthweight

1 rition, birth order, antibiotic use, and low birthweight.

2 s contribute to racial/ethnic differences in birthweight.

3 for Q3, and 3.56 (1.79-7.10) for Q4 for low birthweight.

4 isk factors for under-5 mortality, including birthweight.

5 , maternal morbidity, preterm births, or low birthweight.

6 The primary outcome was birthweight.

7 5% CI 0.90-2.21, I(2)=0.0%, p=0.543) for low birthweight.

8 are associated with maternal anemia and low birthweight.

9 eted weeks of gestation or 1000 g or heavier birthweight.

10 llbirth, miscarriage, preterm birth, and low birthweight.

11 underlyingair pollution-associated shifts in birthweight.

12 on of placental infection and associated low birthweight.

13 risk of non-communicable diseases after low birthweight.

14 .6 million infants were born at term and low birthweight.

15 inst malarial and non-malarial causes of low birthweight.

16 duce overall rates of pre-term birth and low birthweight.

17 w concentrations of ambient air pollution on birthweight.

18 and impaired nutrient transport causing low birthweight.

19 erapy reduces rates of preterm birth and low birthweight.

20 pears to have potent non-malarial effects on birthweight.

21 ting malaria infection, but not at improving birthweight.

22 ated with mortality were prematurity and low birthweight.

23 well as controls born at term or with normal birthweight.

24 rence [RD] -0.05, 95% CI -0.12 to 0.02), low birthweight (0.00, -0.07 to 0.07), and placental malaria

25 Lower birth length (1.9 [1.1-3.2]), lower birthweight (0.5 [0.3-0.9]), and higher birthweight (0.6

26 ower birthweight (0.5 [0.3-0.9]), and higher birthweight (0.6 [0.4-1.0]) were predictive of sensitiza

27 -1.51]) education; and fetal growth (eg, low birthweight 1.30 [1.09-1.55] and small for gestational a

28 mic heart disease (1.10, 1.09-1.11); and low birthweight (1.36, 1.19-1.55) and stillbirth (1.22, 1.06

29 with preterm birth, and higher sEng with low birthweight (1.39; 1.11,3.37), in SPCQ recipients only.

30 (relative risk 1.50, 95% CI 1.24-1.82), low birthweight (1.62, 1.41-1.86), small for gestational age

31 Babies who are term SGA low birthweight (10.4 million in these regions) are at risk

32 an gestational age, 28.3 +/- 2.8 weeks; mean birthweight, 1014.5 +/- 285.0 g), 36 of 92 (39%) demonst

33 We enrolled very low birthweight (1500 g and lower) infants in the primary co

34 y than all other hospital births to have low birthweight (19.1%; SE, 0.5%; vs 7.0%; SE, 0.2%), have r

35 (95% CI: - 1.9, - 0.8) d], and lower average birthweight [ - 19.4 (95% CI: - 36.7, - 2.0) g].

36 .7 per DALY averted for moderate risk of low birthweight, $19.4 per DALY averted for low risk, and $4

37 S, for PCS LoS was significantly longer with birthweight 2.0-2.5 kg, multiple birth and increasing ma

38 LoS >= 6 days; mother's age 30-34 years; low birthweight (2,000-2,500 g); polyhydramnions; cord prola

39 s also suggest an increased risk of term low birthweight (2.62, 1.15-5.93) and preterm low birthweigh

40 quantel did not have a significant effect on birthweight (2.85 kg in both groups, beta=-0.002 [95% CI

41 irthweight (2.62, 1.15-5.93) and preterm low birthweight (3.25, 2.12-4.99).

42 Prospectively enrolled preterm infants with birthweights 500-1,250 g underwent echocardiogram evalua

43 he 12,355,251 live births were classified by birthweight: 500-1,499 g (very LBW [VLBW], n = 139,608),

44 ient supplements during pregnancy had a mean birthweight 77 g greater than children born to mothers t

45 ad worse perinatal outcomes, including lower birthweight (a mean 379 g lower), small for gestational

46 ong infants less than the 5th percentile for birthweight (a proxy for preterm birth) across the clust

47 >50% sensitivity for predicting macrosomia (birthweight above 4,000 g or 90th centile) at birth with

48 birth cohort, we note minimal differences in birthweight across score deciles, but a significant grad

49 maternal morbidity, preterm births, and low birthweight (adverse events).

50 oncentrations at 36 weeks' gestation and low birthweight, an indicator of placental insufficiency.

51 py and enrichment of functional loci between birthweight and 15 cardiometabolic disease traits (CMD).

52 ticipants born very preterm or with very low birthweight and 722 controls, were eligible and included

53 the Early Growth Genetics Consortium GWAS of birthweight and a large biobank-based GWAS of atrial fib

54 that the Mstn KO rabbits exhibited increased birthweight and a significantly increase in the weight r

55 Two novel loci were associated with birthweight and adult coronary artery disease (rs2870463

56 artery disease (rs2870463 in CTRB1) and with birthweight and adult waist circumference (rs12704673 in

57 We investigated the association between birthweight and all-cause mortality and identified major

58 e directionality of the relationship between birthweight and atrial fibrillation, supporting the grow

59 sociation studies, were associated with both birthweight and CMD at a false discovery rate of 5%.

60 (P < 3.3 x 10(-3)) in loci influencing both birthweight and CMD.

61 Low birthweight and decreased postnatal weight gain are know

62 s and tested for the mediating effect of low birthweight and feeding practices.

63 Periodontal treatment tended to increase birthweight and gestational age at the lowest quantiles,

64 ulate the effect of periodontal treatment on birthweight and gestational age in secondary analyses of

65 ddle quantiles, and trended to decrease both birthweight and gestational age in the highest quantiles

66 te SACE for periodontal treatment effects on birthweight and gestational age may be biased towards th

67 our status, delivery mode, offspring gender, birthweight and gestational age.

68 ust observational relationship between lower birthweight and higher risk of cardiometabolic disease i

69 The association of maternal infection with birthweight and length-for-age Z scores (LAZ) at 1 and 1

70 untries of low and middle income to increase birthweight and linear growth during the first 2 years o

71 n pregnancy (IPTp or ITNs) at preventing low birthweight and neonatal mortality under routine program

72 ery, small size for gestational age, and low birthweight and no effect on maternal quality of life, g

73 nt supplementation decreases the risk of low birthweight and potentially improves other infant health

74 stillbirth and neonatal mortality among low-birthweight and preterm babies can be decreased using a

75 The study assessed outcomes of low-birthweight and preterm babies.

76 t since the former is highly correlated with birthweight and the latter with deprivation, we believe

77 ls, we assessed how these outcomes relate to birthweight and to statistically independent measures re

78 Low birthweight and/or respiratory distress were reported in

79 Concordantly, a ~10% decrease in birthweights and ~30% decrease in litter size was observ

80 rths (2520 [5%] less than 5th percentile for birthweight) and 50 control clusters with 50,743 livebir

81 al age, continuous gestational age, and term birthweight) and exposure to a low (1-9) or high ( >= 10

82 ull, beta: 95% CI -4.7: 132.3 to 123.0 g for birthweight, and 0.03: -0.72 to 0.78 weeks for gestation

83 107 to 110.3 g, and -84: -344 to 175.3 g for birthweight, and 0.6: -1.0 to 2.2 weeks, -0.1: -0.5 to 0

84 cated by decreased time to delivery, reduced birthweight, and 100% mortality.

85 ween malaria prevention in pregnancy and low birthweight, and a Poisson model for the outcome of neon

86 h preterm delivery, early-term delivery, low birthweight, and being small for gestational age.

87 fixed ratios) with similar gestational ages, birthweight, and birth dates were selected from the popu

88 w, moderate, and high background risk of low birthweight, and did a separate analysis for HIV-negativ

89 The primary outcomes were preterm birth, low birthweight, and hospital attendances for asthma.

90 aternal obesity is associated with increased birthweight, and obesity and premature mortality in adul

91 Infant mortality, low birthweight, and placental malaria were additional outco

92 ed birthweight, gestational age, risk of low birthweight, and risk of preterm birth among children co

93 dividuals born very preterm or with very low birthweight are at risk of not reaching their full airwa

94 dividuals born very preterm or with very low birthweight, as well as controls born at term or with no

95 r a maternal (or paternal) genetic effect of birthweight associated variants on offspring cardiometab

96 nal analyses in 7,278 participants, <1.3% of birthweight-associated differential methylation is also

97 ylation in neonatal blood is associated with birthweight at 914 sites, with a difference in birthweig

98 Mean birthweight at delivery was 3463 g (SD 660) in the place

99 was associated with an increased risk of low birthweight at term (adjusted odds ratio [OR] 1.18, 95%

100 Primary outcomes included preterm birth, low birthweight at term (LBWT), and small for gestational ag

101 The primary outcome of interest was low birthweight at term (weight <2500 g at birth after 37 we

102 A substantial proportion of cases of low birthweight at term could be prevented in Europe if urba

103 crease of 22% (95% CI 8-33%) in cases of low birthweight at term.

104 e also associated with increased risk of low birthweight at term.

105 Of 18 million low-birthweight babies, 59% were term-SGA and 41% were prete

106 FGR cases (N = 30), defined as birthweight below the 10(th) percentile, were matched wi

107 and small-for-gestational-age (SGA) neonate (birthweight below the fifth percentile).

108 There were differences in birthweight between countries, e.g., India had significa

109 men showed increased length of gestation and birthweight, but did not have a higher risk of macrosomi

110 ternal immunisation reduced the rates of low birthweight by 15% (95% CI 3-25) in both cohorts combine

111 late a predictive model for early-onset FGR (birthweight centile < 3rd/< 10th with absent umbilical e

112 -gestational-age infants (>/=90th customised birthweight centile).

113 r-gestational-age infants (</=5th customised birthweight centile; 6% vs 5%) did not differ between gr

114 The underlying lifetime risk of low birthweight changes slowly with decreasing transmission,

115 to -0.21 or approximately a 96 g decrease in birthweight, comparing the 75th percentile to the median

116 perinatal outcome (lower gestational age and birthweight, containing all cases of perinatal mortality

117 es born preterm and SGA rather than with low birthweight could guide prevention and management strate

118 We collated 1447 country-years of birthweight data (281 million births) for 148 countries

119 data, we smoothed country-reported trends in birthweight data by use of B-spline regression.

120 The RRR for low birthweight declined with increasing prevalence of dhps

121 d paediatric HIV), with the exception of low birthweight, decreased across all regions between 2000 a

122 edible interval [CrI] 530,000-1,240,000) low birthweight deliveries per year.

123 associated with poor outcomes including low birthweight delivery and maternal anemia.

124 7-like variants delivered infants with lower birthweight (difference: -267.99 g; 95% Confidence Inter

125 No such birthweight differences were observed between newborns f

126 ned by the sex- and gestational-age-specific birthweight distributions of the 2017 US Natality file.

127 g countries, the risk of prematurity and low birthweight doubles when conception occurs within 6 mont

128 predicted to greatly reduce incidence of low birthweight, especially in primigravidae.

129 ut remains associated with reductions in low birthweight even in areas where dhps Lys540Glu prevalenc

130 A male baby with a normal birthweight for gestational age (1775 g) and with APGAR

131 ories for women according to first offspring birthweight for gestational age.

132 ociations between maternal age and offspring birthweight, gestational age at birth, height-for-age an

133 2011, and for whom information about infant birthweight, gestational age, and sex was available.

134 ca, and Latin America that recorded data for birthweight, gestational age, and vital statistics throu

135 ars) maternal age were associated with lower birthweight, gestational age, child nutritional status,

136 We analysed birthweight, gestational age, risk of low birthweight, a

137 were reduced in the very preterm or very low birthweight group for FEV(1) (-0.06 [SD 1.03] vs -0.81 [

138 The association of birthweight group with mortality in infancy (<1 y of age

139 fied major causes of mortality for different birthweight groups.

140 revalent in the 1,500-2,499 g and >/=2,500 g birthweight groups.

141 neonates of 32 weeks' gestation or more (or birthweight >/=1500 g) with livebirth denominator data,

142 and three primary outcomes (LGA [defined as birthweight >90th percentile for gestational age], high

143 that of control individuals born with normal birthweight (>2499 g) or at term.

144 Birthweight has also been associated with risk of atrial

145 ancy leads to adverse outcomes including low birthweight; however, contemporary estimates of the pote

146 as associated with reduced prevalence of low birthweight in areas with a Lys540Glu prevalence of more

147 xidative potential (OP) of PM(2.5) on infant birthweight in four European birth cohorts and the mecha

148 (ITNs) significantly reduce the risk of low birthweight in regions of stable malaria transmission.

149 Mediation tests also showed low birthweight in the causal pathway between repeated pregn

150 Pooled RRs for babies who were SGA (with birthweight in the lowest tenth percentile of the refere

151 small-for-gestational-age (SGA; babies with birthweight in the lowest third percentile and between t

152 HDL-C more strongly associated with healthy birthweight in women with BMI >=25.

153 However, low birthweight includes babies born preterm and with fetal

154 clinical gestational age is associated with birthweight independent of gestational age, sex, and anc

155 ry preterm (1.53, 1.22-1.92), or to have low-birthweight infants (1.30, 1.04-1.62) than were those wh

156 hthalmitis were higher for premature and low-birthweight infants and those identified with perinatal

157 al infections (RVIs) among admitted very-low-birthweight infants in our neonatal department.

158 ased use of antenatal corticosteroids in low-birthweight infants in the intervention groups, neonatal

159 In Guinea-Bissau, low-birthweight infants were randomized to early (interventi

160 In a randomized trial of 3003 very low birthweight infants, display of the HeRO score reduced m

161 New studies in very low-birthweight infants, infants with congenital heart disea

162 recede necrotising enterocolitis in very low birthweight infants.

163 ority trial with healthy, full-term (>2.5 kg birthweight) infants aged 8 weeks (+/- 7 days) at six we

164 Low birthweight is a significant risk factor for neonatal an

165 ) of maternal SNPs associated with offspring birthweight is also associated with offspring cardiometa

166 Abnorml birthweight is associated with cardiometabolic disease r

167 Birthweight is associated with health outcomes across th

168 sality of air pollution-associated shifts in birthweight is better supported, substantiating the need

169 es from developing country settings in which birthweight is either not available or accurate.

170 A prominent cause of low birthweight is infection with Plasmodium falciparum duri

171 ed by maternal SNPs that influence offspring birthweight, is unlikely to be a major determinant of ad

172 reterm delivery (S-shaped, p<0.0001) and low birthweight (J-shaped, p=0.0001); the adjusted odds rati

173 000 (94,000-236,000 95% crI) preventable low birthweight (LBW) deliveries.

174 Low birthweight (LBW) is associated with increased mortality

175 Low birthweight (LBW) of less than 2500 g is an important ma

176 en periodontal status and preterm birth, low birthweight (LBW) or preeclampsia.

177 ITNs to pregnant women and the impact on low birthweight (LBW).

178 nfection during pregnancy on the risk of low birthweight (LBW; <2,500 g) may depend upon maternal nut

179 ve GWG showed increased length of gestation, birthweight, length, and head circumference, and were mo

180 regnancy BMI or GWG and length of gestation, birthweight, length, and head circumference.

181 ytomegalovirus infection was associated with birthweight less than 1 kg, maternal age younger than 25

182 We screened infants with birthweight less than 1500 g who met criteria for treatm

183 estriction, and not all these infants have a birthweight less than 2500 g.

184 cting as an early life stressor, we examined birthweight, litter size, maternal cannibalism, and epig

185 re preterm birth at less than 36.5 weeks and birthweight lower than 2575 g respectively.

186 35-39 years; placenta weight 1,000-1,500 g; birthweight < 2,000 g; maternal age >= 45 years; pre-del

187 performed in 37 consecutive FGR (defined as birthweight <10th centile) and 37 normally grown fetuses

188 eclampsia, small-for-gestational-age infant (birthweight <10th percentile), pregnancy loss, or venous

189 eks] and 90 [10%] small-for-gestational age [birthweight <10th percentile]).

190 sia/pre-eclampsia; mother's age 30-34 years; birthweight <2,000 g; polyhydramnios and pre-term gestat

191 weeks; gestation 41+ weeks; oligohydramnios; birthweight <2,500 g, maternal age >= 35 and cord prolap

192 m (at <32 weeks' gestation) or with very low birthweight (<1501 g) is unknown.

193 and SP plus azithromycin (SPAZ) reduces low birthweight (<2,500 g) in women without malarial and rep

194 Neonates with a low birthweight (<2.5 kg) were more likely (1.7, 1.1-2.8) to

195 red rates of livebirth, multiple births, low birthweight (<2.5 kg), preterm birth (<37 weeks), and se

196 : -466.43 g,-69.55 g) and higher odds of low birthweight (<2500 g) (Odds Ratio [OR] 5.41; 95% CI:0.99

197 Babies with low birthweight (<2500 g) are at increased risk of early mor

198 0-180 days postpartum, the incidence of low birthweight (<2500 g), and the incidence of laboratory-c

199 GA and preterm-SGA), and the relation to low birthweight (<2500 g), in 138 countries of low and middl

200 sometimes has adverse outcomes including low birthweight (<2500 g), pre-term birth (<37 weeks), growt

201 gnificant associations of amblyopia with low birthweight (<2500 g), preterm birth (<37 weeks), matern

202 (composite of small for gestational age, low birthweight [<2,500 g], or preterm birth [<37 wk]) in pa

203 tal health and risk for preterm birth or low birthweight, making periodontitis a potentially modifiab

204 (NTR4153), 11 NEC cases were gestational age/birthweight matched with controls (ratio of 1:2).

205 he following major confounders: deprivation, birthweight, maternal age, sex, and multiple birth.

206 in, pre-pregnancy BMI, preterm delivery, low birthweight, maternal antibiotic use, and infection duri

207 ncy at birth, infant mortality, low and high birthweight, maternal mortality, nutritional status, edu

208 rising from stillbirths, neonatal death, low birthweight, mild and moderate maternal anaemia, and cli

209 th, very small for gestational age, very low birthweight, miscarriage, or neonatal death, although fe

210 he risks of MiP and malaria-attributable low birthweight (mLBW) in unprotected pregnancies (i.e., tho

211 DALYs) for fetal loss or neonatal death, low birthweight, moderate or severe maternal anaemia, and cl

212 thnicity, mode of delivery, gestational age, birthweight, mother's age, mother's index of multiple de

213 analyses included cesarean-section delivery, birthweight, multiple birth, and infant survival status.

214 C) in very low birthweight (VLBW) and normal birthweight (NBW) infants are rare.

215 lbirth, preterm, small-for-gestational age), birthweight, neonatal death or LAZ.

216 In 2002-2004, we randomized 4345 normal birthweight neonates to NVAS (50 000 IU retinyl palmitat

217 Higher-birthweight newborns from HbAC mothers may have a surviv

218 Obstetric outcomes (birthweight, obstetric or neonatal complications, and ad

219 s with younger maternal age remained for low birthweight (odds ratio [OR] 1.18 (95% CI 1.02-1.36)], p

220 Nurses with a birthweight of >=4000 g had a 32% greater risk for breas

221 vely weak for all outcomes-eg, difference in birthweight of -31 g (95% CI -85 to 22) and 1.56 percent

222 d parental characteristics-eg, difference in birthweight of -60 g (95% CI -86 to -34) and 2.15 percen

223 t 6 months; were a singleton birth and had a birthweight of 2 kg or more; had no clinically observed

224 fty-three patients with a mean gestation and birthweight of 38.8 +/- 2.0 weeks and 3.33 +/- 0.6 kg, r

225 Mean birthweight of 742 babies with mothers assigned to FNP w

226 gned to FNP was 3217.4 g (SD 618.0), whereas birthweight of 768 babies assigned to usual care was 319

227 ticipants were healthy newborn babies with a birthweight of at least 2.5 kg, for whom informed consen

228 We regarded SGA as a birthweight of less than the 10th percentile for gestati

229 Average birthweight of non-Hispanic white infants was 3381 g, wh

230 tobacco use by the mother at late pregnancy, birthweight of the baby, the proportion of women with a

231 The median gestational age at birth and birthweight of the infants were 27 weeks and 909 g, resp

232 ined at 48 hours postpartum in newborns with birthweights of 2,250 g or more.

233 71, p-trend = 0.09) compared with those with birthweights of 3000-3499 g.

234 ody mass in anthropoids are used to estimate birthweights of extinct hominid taxa.

235 ed a genetic approach to study the effect of birthweight on atrial fibrillation.

236 lian randomization to consider the impact of birthweight on incident atrial fibrillation using summar

237 etal death in the third trimester (>/=1000 g birthweight or >/=28 completed weeks of gestation).

238 were estimated worldwide in 2008 (>/=1000 g birthweight or >/=28 weeks of gestation).

239 r inclusion if they contained information on birthweight or LBW prevalence for livebirths.

240 adj) 2.04, 95% CI [1.60-2.59]), previous low birthweight (OR(adj) 2.22, 95% CI [1.79-2.75]), nullipar

241 n third trimester maternal lipid profile and birthweight outcomes are driven by preconception lipids

242 roup and were differentially associated with birthweight outcomes, with HDL-C more strongly associate

243 -like illness, influenza in infants, and low birthweight over the entire course of the study, indicat

244 nfant characteristics (sex, gestational age, birthweight, parity and breast feeding), maternal charac

245 ficantly associated with reduced odds of low birthweight (PE 21%, 14-27; IRR 0.792, 0.732-0.857), as

246 Metformin has no significant effect on birthweight percentile in obese pregnant women.

247 estational age, parity, and sex-standardised birthweight percentile of liveborn babies delivered at 2

248 Low birthweight percentile was associated with increased fov

249 Birthweight percentiles were lower in neonates prenatall

250 Low birthweight, pre-term birth and pre-eclampsia have been

251 gestational age, small for gestational age, birthweight, pregnancy loss or miscarriage, or pre-eclam

252 AGP levels were strongly associated with low birthweight, preterm birth and small-for-gestational age

253 mposite adverse birth outcome defined as low birthweight, preterm birth, or small for gestational age

254 birthweight, very low birthweight, term low birthweight, preterm low birthweight, small for gestatio

255 participant data) that reported data on low birthweight (primary outcome) and malaria by sulfadoxine

256 antified the relative effect of treatment on birthweight (primary outcome) attributed to preventing p

257 rthweight at 914 sites, with a difference in birthweight ranging from -183 to 178 grams per 10% incre

258 th uncomplicated pregnancies (individualized birthweight ratio [IBR] >20th percentile and delivery >3

259 hildhood and adolescence, but not adulthood. Birthweight-related CpGs overlap with some Bonferroni-si

260 ulthood compared to average birth length and birthweight, respectively.

261 on level, kilocalories, infant age, sex, and birthweight revealed that infant cognitive development s

262 ements resulted in greater reductions in low birthweight (RR 0.81, 95% CI 0.74-0.89; p value for inte

263 Both mean gestational age and mean birthweight seems significantly greater for liver transp

264 sability-adjusted life-years (DALYs) for low birthweight, severe to moderate anaemia, and clinical ma

265 stic regression models, adjusted for child's birthweight, sex, age, ethnic origin, parental education

266 herapy is associated with preterm birth, low birthweight, small for gestational age, and stillbirth,

267 The risk of very low birthweight, small for gestational age, severe small for

268 rthweight, term low birthweight, preterm low birthweight, small for gestational age, very small for g

269 er, date of birth, gestational age at birth, birthweight, stage of ROP at presentation, initial treat

270 including gender, gestational age at birth, birthweight, stage of ROP at presentation, prior treatme

271 iorespiratory disease is associated with low birthweight suggesting the importance of the development

272 ery preterm birth, low birthweight, very low birthweight, term low birthweight, preterm low birthweig

273 Newborns from HbAC mothers had higher birthweights than those from HbAA mothers among women in

274 acental infection and associated risk of low birthweight to estimate the number of women who would ha

275 ial reductions in neonatal mortality and low birthweight under routine malaria control programme cond

276 ly a 2-5 fold risk of birthing neonates with birthweights under the 3(rd), 5(th), 10(th) and 20(th) c

277 s did not account for significant portion of birthweight variations for any race.

278 omes: preterm birth, very preterm birth, low birthweight, very low birthweight, term low birthweight,

279 and early childhood caries (ECC) in very low birthweight (VLBW) and normal birthweight (NBW) infants

280 very was 30.7 weeks (IQR 29.1-32.1) and mean birthweight was 1019 g (SD 322).

281 f these neonates was 35.0 weeks (SD 4.6) and birthweight was 2384 g (1007).

282 The median birthweight was 3,300 g (IQR 2,980-3,615).

283 t associated with dysglycaemia, but a higher birthweight was associated with decreased risk of the di

284 n, we found that a 1-SD genetic elevation of birthweight was associated with increased risk of atrial

285 A higher birthweight was consistently associated with an adult bo

286 Overall, birthweight was higher among neonates of women randomly

287 No significant effect on low birthweight was identified (six studies, >1.9 million in

288 s for multiple birth, preterm birth, and low birthweight were all smaller in older than in younger wo

289 had resulted and data on gestational age and birthweight were complete).

290 ants were born very preterm or with very low birthweight were excluded.

291 Severe ROP and low birthweight were related to neuronal and axonal damage i

292 69 (83%) of 83 cases with known birthweight were small for gestational age, compared wit

293 Preterm birth and low birthweight were the most common adverse pregnancy outco

294 on at delivery and health outcomes including birthweight, which is also determined by a wide range of

295 ; maternal mortality in ten populations; low birthweight with the rate difference greater than 2% in

296 e greater than 2% in three populations; high birthweight with the rate difference greater than 2% in

297 maternal prepregnancy BMI, mode of delivery, birthweight z score, sex, and time.

298 ation between mixtures of air pollutants and birthweight z-scores (standardized for gestational age)

299 There was a negative association with birthweight z-scores and exposure to mixtures of air pol

300 Shifts in birthweight z-scores from prenatal exposure to PM(2.5),